The effect of the dietary flavonoid galangin on the metabolism of 7,12-dimethylbenz [a]anthracene (DMBA), the activity of cytochrome P 450 1A1 (CYP1A1), and the expression of CYP1A1 in MCF-7 human breast carcinoma cells was investigated. Galangin inhibited the catabolic breakdown of DMBA, as measured by thin-layer chromatography, in a dose-dependent manner. Galangin also inhibited the formation of DMBA-DNA adducts, and prevented DMBA-induced inhibition of cell growth. Galangin caused a potent, dose-dependent inhibition of CYP1A1 activity, as measured by ethoxyresorufin-O-deethylase activity, in intact cells and in microsomes isolated from DMBAtreated cells. Analysis of the inhibition kinetics by double-reciprocal plot demonstrated that galangin inhibited CYP1A1 activity in a noncompetitive manner. Galangin caused an increase in the level of CYP1A1 mRNA, indicating that it may be an agonist of the aryl hydrocarbon receptor, but it inhibited the induction of CYP1A1 mRNA by DMBA or by 2,3,5,7-tetrachlorodibenzo-p-dioxin (TCDD). Galangin also inhibited the DMBA-or TCDD-induced transcription of a reporter vector containing the CYP1A1 promoter. Thus, galangin is a potent inhibitor of DMBA metabolism and an agonist/antagonist of the AhR, and may prove to be an effective chemopreventive agent.
Numerous epidemiological studies have demonstrated that diets rich in fruits and vegetables are protective against several forms of cancer (Steinmetz and Potter, 1996) , and much attention has been focused on whether naturally occurring dietary components can modify the mutagenic and carcinogenic effects of environmental carcinogens. 7,12-dimethylbenz [a] anthracene (DMBA), a model compound which induces mammary tumorigenesis in rodents (Huggins et al, 1961) , is a member of one such class of carcinogen, the aryl hydrocarbons. Aryl hydrocarbons bind and activate the aryl hydrocarbon receptor (AhR), which induces the transcription of a number of genes (Rowlands and Gustafsson, 1997) , including the cytochrome P 450 1A (CYP1A) enzyme family. CYP1As mediate the oxidative catabolism of aryl hydrocarbons, generating genotoxic metabolites which can bind specific residues of DNA, introducing mutations in key genes and resulting in cellular transformation (Dipple, 1995) . Inhibition of the metabolic activation of carcinogens, either through inhibition of the AhR-mediated signal transduction pathway or direct enzyme inhibition, is believed to be an important mechanism in chemoprevention.
Flavonoids are among the most abundant of phytochemicals and much attention has been focused recently on the effect of flavonoids on chemically induced in vivo models of carcinogenesis. Flavonoids consist of a diverse group of polyphenolic derivatives of benzo-γ-pyrone that are ubiquitous in foods of plant origin such as vegetables, fruit, tea and wine (Formica and Regelson, 1995) . Dietary intake of flavonoids has been estimated at 1 g per day (Kuhnau, 1976) , but recent studies have indicated that consumption varies widely . In vivo studies have shown that some flavonoids are effective in preventing chemically induced cancer in rodents, including DMBA-induced mammary cancer (Verma et al, 1988; Lamartiniere et al, 1995) . Flavonoids exert a multiplicity of biochemical actions that are believed to be an important part of the chemopreventive effect of plant-based diets. Various flavonoids are potent antioxidants (Kono et al, 1997; Noda et al, 1997) , inhibit lipoxygenase and cyclooxygenase (Mirzoeva and Calder, 1996) , affect the activity of several hepatic enzymes involved in activation and detoxification of carcinogens (Canivenc-Lavier et al, 1996) , inhibit cellular proliferation (Tsyrlov et al, 1994; Siess et al, 1995; Moon et al, 1998) , and induce apoptosis of tumour cells (Csokay et al, 1997) . Galangin, a member of the flavonol class of flavonoids, is present in high concentrations in Alpina officinarum (common name: China or India root), which has been used as a spice and as a herbal medicine for a variety of ailments in Asia for centuries. Galangin has been shown to inhibit the proliferation of breast tumour cells (So et al, 1996 (So et al, , 1997 , and to inhibit the cytochrome P 450 -dependent hydroxylation of the aryl hydrocarbon benzo[a]pyrene in human liver microsomes (Buening et al, 1981) .
For this report we have examined the effects of galangin on the carcinogen activation pathway mediated by the AhR. We have used the MCF-7 human breast carcinoma cell line because it is derived from the target tissue of DMBA, the mammary epithelium, and because AhR function and carcinogen activation has been well characterized in these cells (Christou et al, 1994; Moore et al, 1994; Dohr et al, 1995; Wang et al, 1995) . Furthermore, a recent study has demonstrated that MCF-7 cells are similar to normal human mammary epithelial cells with regard to AhR
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Cellular Defense and Carcinogenesis Section, Basic Research Laboratory, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, NIH, Frederick, MD 21702-1201, USA expression and CYP1A1 activity (Larson et al, 1998) . We demonstrate that galangin inhibits the activation of DMBA by inhibiting AhR function and CYP1A1 enzyme activity, and thus may be a promising candidate for in vivo chemoprevention study.
MATERIALS AND METHODS

Materials
Except as noted, all chemicals were from Sigma (St Louis, MO, USA). All culture vessels were from CoStar (Cambridge, MA, USA). Galangin (Aldrich, Milwaukee, WI, USA) was dissolved in dimethylsulphoxide (DMSO) and stored at -20°C.
Cell culture
MCF-7 cells (American Type Culture Collection, Rockville, MD, USA) were grown in RPMI-1640 supplemented with 2 mM glutamine and 10% fetal bovine serum (all from BioFluids, Rockville, MD, USA). Cells were sub-cultured weekly using 0.25% trypsin/0.05% EDTA (BioFluids). All experiments were carried out at 37°C and 5% carbon dioxide on confluent cells in growth medium, except where indicated.
Measurement of DMBA metabolism
All steps were carried out in the dark or under yellow light. MCF-7 cells in 175 cm 2 flasks were incubated in 12 ml of growth medium containing 0.1 µg ml -1
[ 3 H]DMBA (Amersham, Arlington Heights, IL, USA) in the presence of DMSO (control), 1 µM, or 10 µM galangin. After 24 h, 1 ml of the medium was removed and extracted with 1 ml ethyl acetate. [ 3 H]DMBA was separated from metabolites by thin-layer chromatography. A total of 5 µl of the organic phase was applied to a 20 × 20 cm 2 silica thin-layer chromatography sheet with fluorescent indicator (Kodak, Rochester, NY, USA). Chromatography was performed in n-hexane for 80 min. The sheet was dried and 12 1.7-cm strips were cut, placed in 20 ml BSC-NA organic scintillation fluid (Amersham) and counted. The parent compound migrated to the seventh and eighth strips while the metabolites migrated to the first two strips (counted from the point of application). Spontaneous decomposition of [ 3 H]DMBA was determined by incubating flasks without cells under the same conditions. The amount of metabolites formed in blank flasks (20 ± 0.58%; n = 3) was subtracted from the other incubations.
Measurement of DMBA-DNA adduct formation
Confluent cultures of MCF-7 cells in 75 cm 2 flasks were exposed to 0.1 µg ml -1 [ 3 H]DMBA in the presence of the indicated concentrations of galangin for 8 h. Cells were washed twice with cold phosphate-buffered saline (PBS), trypsinized and pelleted. Nuclei were isolated by incubating the cells for 10 min on ice in 10 mM Tris-HCl, pH 7.5, with 320 mM sucrose, 5.0 mM magnesium chloride and 1% Triton X-100. The nuclei were pelleted by centrifugation at 800 g for 10 min at 4°C, and this digestion was repeated once. Nuclei were then lysed with 1% sodium dodecyl sulphate (SDS) in 0.5 M Tris, 20 mM EDTA and 10 mM NaCl, pH 9.0, followed by treatment with 20 mg ml -1 proteinase K for 6 h at 48°C. Protein and peptides were precipitated by the addition of NaCl to final concentration of 1 M and centrifuged at 500 g for 30 min at 4°C. Genomic DNA was then isolated from supernatant by repeated ethanol precipitation as described in Miller et al (1988) . DNA isolated by this method exhibited a 260/280 ratio of > 1.9. The amount of DNA was measured by spectrophotometry and the adducts were quantified by liquid scintillation counting in Ecoscint A (National Diagnostics, Atlanta, GA, USA).
Measurement of cell growth
MCF-7 cells were plated out in 24-well plates at 25 000 cell per well and allowed to attach for 24 h. DMBA was added at the indicated concentrations with either DMSO (control) or 5.0 µM galangin in fresh media. Total cell growth was assayed after 3 days using sulphorhodamine (Rubinstein et al, 1990 ).
CYP1A1 activity in intact MCF-7 cells
MCF-7 cells in 24-well plates were treated with 1 ml growth medium containing 1 µM DMBA for 24 h in the presence of DMSO or the indicated concentrations of galangin. At the end of the incubation, the medium was removed and the wells were washed two times with fresh medium. Ethoxyresorufin-O-deethylase (EROD) activity, which is a specific assay of the bioactivation capacity of CYP1A1, was determined in intact cells as described in Kennedy and Jones (1994) using 5 µM ethoxyresorufin (ETRF) in growth medium as a substrate in the presence of 1.5 mM salicylamide to inhibit conjugating enzymes (Lubinski et al, 1994) . The assay was carried out at 37°C. The fluorescence of resorufin generated by the conversion of ETRF by CYP1A1 was measured every 10 min for 60 min in a CytoFlor II multiwell fluorescence plate reader (PerSeptive Biosystems, Framingham, MA, USA), with an excitation of 530 nm and emission at 590 nm.
Microsomal CYP1A1 activity
MCF-7 cells were treated with 1 µM DMBA for 24 h to induce CYP1A1 EROD activity. Microsomes were isolated as follows: the cells were washed once with PBS, trypsinized and pelleted by centrifugation at 800 g for 10 min at 4°C. The pellet was washed in PBS, repelleted, then resuspended in 0.25 M sucrose, 10 mM TrisHCl, pH 7.5, with protease inhibitors (100 µg ml -1 phenylmethylsulphonylfluoride, 300 µg ml -1 EDTA, 0.5 µg ml -1 leupeptin, 0.5 µg ml -1 aprotinin and 0.7 µg ml -1 Pepstatin A). The cells were sonicated for 30 s on ice using a Branson Sonifier at setting 2. The sonicate was centrifuged at 10 000 g for 10 min at 4°C and the supernatant was centrifuged at 500 000 g for 15 min at 4°C. The resulting microsomal pellet was resuspended in the above buffer and the protein assayed by the Bradford method (1976) . Aliquots of microsomes were stored at -80°C. CYP1A1 activity was determined by EROD assay in the following manner: for Figure 5A , 10 µg of microsomes were brought up to 100 µl with PBS, pH 7.2, 400 nM ETRF was added, along with DMSO or the indicated concentrations of galangin. The reaction was initiated by the addition of 250 µM NADPH. The reaction mixture was transferred to a 96-well plate and EROD activity was determined in a Cytoflor II Fluorescence Plate Reader as described above. For Figure 5B , 250 µM NADPH and 100-1600 nM ETRF were added to 3 ml of PBS, pH 7.2, 410 µl aliquots were removed to which DMSO or the indicated concentration of galangin were added. The reaction was initiated by the addition of 45 µg of microsomal protein (final volume was 450 µl) and gently vortexed. Four 100-µl aliquots (10 µg per assay) of each were removed, placed in a 96-well plate and assayed as above. A standard curve was constructed using resorufin.
Reverse transcription polymerase chain reaction (RT-PCR)
Confluent MCF-7 cells were treated with a combination of galangin and 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 250 nM DMBA for 6 h, or with galangin alone for 24 h. The cells were washed twice with PBS and total RNA was isolated using Trizol reagent (GibcoBRL, Gaithersburg, MD, USA). Semi-quantitative RT-PCR for CYP1A1 and glyceraldehyde-3-phosphate dehydrogenase (GPDH) was performed in the presence of 1.5 µCi [ 32 P]dATP (DuPont/NEN, Wilmington, DE, USA) using the primer sequences and conditions of Dohr et al (1995) . cDNA was synthesized from 10 µg total RNA using a Stratagene RT-PCR kit (LaJolla, CA, USA) as instructed. The optimum cycle number that fell within the exponential range of response for both CYP1A1 (23 cycles) and GPDH (19 cycles) was used. Following PCR, 5 µl of high-density sample buffer was added to the samples and they were subjected to electrophoresis on a 10% Tris-borate-EDTA (TBE) gel in 1 × TBE running buffer (all components from Novex, San Diego, CA, USA). The gel was dried and the results were visualized and quantified on a BioRad GS-363 Molecular Imaging System (Hercules, CA, USA). Graphs of the resulting data were generated by normalizing CYP1A1 to GPDH.
CAT-β-galactosidase assays
MCF-7 cells were plated at 60 000 cells per well in 24-well plates. After 24 h the cells were transiently transfected with 12.0 µg of a chloramphenicol acetyltransferase (CAT) reporter vector containing the full length rat CYP1A1 promoter (pMC6.3K; Sogawa et al, 1986) using LipofectAmine (GibcoBRL) as directed. To control for transfection efficiency, the cells were co-transfected with 1.0 µg of pCMZ vector containing β-galactosidase (Clonetech Labs, Palo Alto, CA, USA). After a further 24 h, the cells were treated with 1 nM TCDD or 250 nM DMBA in the presence of DMSO (control) or galangin for 6 h. The amount of CAT transcription was determined using an ELISA assay (Boehringer Mannheim, Indianapolis, IN, USA) as directed. Activity of β-galactosidase was determined by the method of Rosenthal (1987) . The amount of CAT transcription was normalized to β-galactosidase transcription.
Statistical analysis
Statistical analyses were performed using StatView Statistical Analysis software (SAS Institute, San Francisco, CA, USA). Differences between group mean values were determined by a one-factor analysis of variance (ANOVA), followed by Fisher PSLD post-hoc analysis for pair wise comparison of means.
RESULTS
Effect of galangin on the metabolism of [ 3 H]DMBA
MCF-7 cells were incubated with [ 3 H]DMBA in the presence or absence of galangin for 24 h and the catabolism of DMBA was determined by thin-layer chromatography. After 24 h, 65 ± 2.1% (3.1 ± 0.1 nmoles of DMBA per flask per 24 h) of the parent compound had been converted to metabolites in untreated cells. Galangin caused a dose-dependent inhibition of [ 3 H]DMBA catabolism (Figure 1) .
The effect of galangin on the formation of adducts between metabolites of DMBA and DNA in MCF-7 cells was examined. In control cultures, exposure to 0.1 µg ml -1 [ 3 H]DMBA for 8 h resulted in the formation of 3035 ± 168 fmoles adducts per mg DNA. Exposure of the cells to [ 3 H]DMBA in the presence of galangin inhibited DMBA-DNA adduct formation in a dosedependent manner (Figure 2) .
We measured the growth of MCF-7 cells after 3 days of incubation with increasing concentrations of DMBA in the presence or absence of 5 µM galangin. Galangin completely inhibited DMBAinduced cytotoxicity at the concentrations tested (Figure 3 ). Galangin at the tested concentration had no effect on cell growth by itself (data not shown).
Effect of galangin on CYP1A1 activity
We measured the activity of CYP1A1 using the EROD assay, which is specific for the CYP1A1 enzyme family. There was no EROD activity in MCF-7 cells in the absence of DMBA treatment. Treatment of cells with DMBA caused a dose-dependent increase in EROD activity (data not shown). We measured the EROD activity in intact cells which had been exposed to 1 µM DMBA in the presence of galangin. Galangin caused a dose-dependent inhibition of EROD activity with an IC 50 of less than 1 µM (Figure 4) . The EROD activity in microsomes isolated from cells treated with 1 µM DMBA was potently inhibited by galangin in a dose-dependent manner, with an IC 50 of approximately 30 nM ( Figure 5A ). Microsomal EROD activity with or without galangin was also measured in the presence of different substrate concentration and the kinetics of enzyme inhibition by galangin were analysed by double-reciprocal (Lineweaver-Burk) analysis ( Figure 5B ). The V max of the enzyme shifted from 5.55 pmoles per min per 10 µg microsomes in the absence of galangin to 2.56 or 1.67 pmoles per min per 10 µg in the presence of 25 or 50 nM galangin, while the K m remained unchanged, indicating a non-competitive type of inhibition.
Effect of galangin on CYP1A1 expression
Treatment of MCF-7 cells with 1 nM of the known AhR ligand TCDD for 6 h resulted in a 40-fold increase in CYP1A1 mRNA compared to DMSO control, as determined by semi-quantitative RT-PCR. This increase was inhibited by galangin in a dosedependent manner ( Figure 6A The CYP1A1 activity in 10 µg of microsomes was measured by EROD assay in the presence of 400 nM ETRF and the indicated concentrations of galangin. Each point represents the average of 4 determinations ± s.e. EROD activity in controls was 2.33 ± 0.1 pmoles per min per 10 µg. EROD activity in all galangin-treated samples was statistically different from controls (P < 0.05). (B) EROD activity in 10 µg of microsomes was measured in the presence of 0 (s s), 25 (x x), or 50 nM (q q) galangin and 100-1600 nM ETRF and a doublereciprocal (Lineweaver-Burk) plot was generated. Each point represents the mean of 4 determinations DMBA resulted in a tenfold increase in CYP1A1 mRNA, which was also inhibited by galangin ( Figure 6B ).
The effect of galangin on the transcription of a CAT reporter vector controlled by the CYP1A1 promoter was determined by transient transfection studies. Treatment of transfected cells for 6 h with 1 nM TCDD caused a sevenfold increase in CAT transcription. This was inhibited in the presence of galangin in a dosedependent manner (Figure 7 ). DMBA at 250 nM induced a threefold increase in transcription that was also inhibited by galangin.
Treatment of MCF-7 cells with galangin alone for 24 h resulted in a dose-dependent increase in CYP1A1 mRNA (Figure 8 ). This increase was blocked by the RNA polymerase inhibitor actinomycin D, indicating that the increase in mRNA was the result of transcriptional activation (data not shown).
DISCUSSION
Current cancer prevention strategy is based on the growing awareness of the powerful anti-carcinogenic activities of plant-based diets. The central tenet of this strategy is that minor dietary constituents inhibit carcinogenesis through different mechanisms of action. The steps between exposure to a procarcinogen and the transformation of a normal cell to a cancer cell begin with the activation of the procarcinogen by cytochrome P 450 enzyme(s). This generates metabolites which may be converted to easily excreted forms by Phase II enzymes, but also generates epoxides which are highly electrophilic and carcinogenic, capable of reacting with DNA and causing mutations. One mechanism of action of the so-called 'blocking' type of chemopreventive agent, as classified by Wattenburg (1985) , is the inhibition of the procarcinogen activation step. In the present study we have investigated the effect of the dietary flavonoid galangin on the carcinogen activation pathway mediated by the AhR. Galangin is of particular interest because its effects on other in vitro mechanisms relevant to chemoprevention has been extensively studied (Critchfield et al, 1994; Eaton et al, 1996; Kao et al, 1998) , but there is, to our knowledge, no study which has examined its effect on the AhR and the pathway it regulates.
We assessed the effect of galangin on the activation of DMBA. Galangin inhibited the catabolic breakdown of DMBA (Figure 1 ). Since the parent compound does not react with DNA, we hypothesized that galangin would decrease DMBA-DNA adduct formation, which proved true (Figure 2 ). In the tissue culture setting, DMBA inhibits cell growth because of DNA adduct formation. We reasoned that decreased adduct formation would therefore reduce the cytotoxicity of DMBA in vitro. In fact, at the concentration tested, galangin completely abolished the cytotoxic effect of DMBA (Figure 3 ). Galangin itself was not cytotoxic at the tested concentration. These experiments indicate that galangin inhibits the activation of DMBA to genotoxic metabolites. There is, to our knowledge, no study assessing the physiologically relevant concentrations that galangin may achieve, but other flavonoids have been measured in the plasma and some tissues of humans in the range of concentrations used in this study (Morton et al, 1997; Hollman and Katan, 1998) . Moreover, these concentrations correspond to plasma concentrations found in rats fed with a flavonoidenriched diet (Manach et al, 1995) . RT-PCR was performed, the product was subjected to electrophoresis, and the gel was analysed and quantified with a phosphoimager. For graph, CYP1A1 mRNA was normalized to GPDH mRNA. n = 3 ± s.e. The level of CYP1A1 mRNA in all galangin-treated samples was statistically different from the TCDD-or DMBA-treated cultures (P < 0.05)
We next examined the mechanism(s) of galangin's action. The activity of CYP1A1 was measured by EROD assay, a specific indicator of the CYP1A1 bioactivation capabilities. Under conditions of AhR activation, the major DMBA activating isozyme in MCF-7 cells is CYP1A1 (Christou et al, 1994) . These cells also express CYP1B1, but it is unclear whether this isozyme can metabolize DMBA (Shimada et al, 1997) , or whether CYP1B1 possess significant EROD activity (Dohr et al, 1995; Shimada et al, 1997) . Co-treatment of the cells with DMBA and increasing concentrations of galangin resulted in a dose-dependent inhibition of DMBA-induced EROD activity in intact cells (Figure 4 ). We could not determine, from this experiment, whether galangin's effect was as a result of inhibition at the enzyme level or through a disruption of the signal transduction pathway leading to the transcriptional activation of the CYP1A1 gene. We therefore performed EROD assays on microsomes isolated from DMBAtreated cells. Galangin proved to be a potent inhibitor of microsomal EROD activity ( Figure 5A ). Previous studies have shown that the related flavonol quercetin inhibits EROD activity in rat hepatic microsomes in a competitive fashion (Sousa and Marletta, 1985) , a result we confirmed in MCF-7 microsomes (data not shown). Analysis of the kinetics of inhibition by galangin, however, revealed that galangin inhibits EROD activity in a noncompetitive manner ( Figure 5B ). Thus, the interaction of galangin with CYP1A1 is different than the structurally similar quercetin.
DMBA causes the transcriptional activation of the CYP1A1 gene through the AhR. Although the results of the microsomal EROD assays indicate that direct enzyme inhibition by galangin can account for the decrease in DMBA-induced EROD activity in intact cells, we also tested the hypothesis that galangin may disrupt the transciptional activation of CYP1A1. When MCF-7 cells were treated with 250 nM DMBA for 6 h, there was an approximately tenfold increase in CYP1A1 mRNA compared to DMSO control. Co-treatment with galangin caused a dose-dependent inhibition of the DMBA-induced increase in CYP1A1 mRNA ( Figure 6B ).
Galangin also inhibited the increase in CYP1A1 mRNA by the prototypical AhR ligand TCDD ( Figure 6A ). Galangin also inhibited the DMBA-or TCDD-induced transcription of CAT in a reporter vector controlled by the CYP1A1 promoter (Figure 7) . We also observed that treatment of the cells with galangin alone for a longer period of time (24 h) could induce a mild increase (compared to DMBA or TCDD) in CYP1A1 mRNA (Figure 8 ). This increase was blocked by the RNA polymerase inhibitor actinomycin D, which prevents de novo RNA synthesis resulting from transcriptional activation (data not shown). These results are consistent with the hypothesis that galangin is a weak ligand of the AhR and is able to compete for the AhR with traditional activators of the receptor, resulting overall in a decrease in CYP1A1 mRNA caused by other, more potent AhR ligands. The induction of CYP1A1 mRNA and the inhibition of CYP1A1 EROD activity by galangin may indicate that it is a natural substrate of this metabolic pathway in MCF-7 cells, but this was not examined in the present study.
Known ligands of the AhR are, for the most part, man-made chemicals; natural ligands have been postulated but, with the exception of indolo[2,3]-carbazole (Jellinck et al, 1993) , remain unidentified. We have hypothesized elsewhere (Ciolino et al, 1998 ) that dietary polyphenolic compounds are natural ligands of the AhR and galangin appears to be such a compound. These experiments demonstrate that galangin inhibits carcinogen activation in MCF-7 cells at two levels: through direct inhibition of CYP1A1 enzyme activity and by inhibiting the increase in CYP1A1 transcription caused by AhR ligands. There is no study, to our knowledge, on the chemopreventive effect of galangin in animal models of carcinogenesis. Based on our data, galangin may be a promising candidate for in vivo chemoprevention studies. 
